NCT03672968No Longer Available不适用
EAP Single Patient: Safety of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected With G11778A ND4 Leber Hereditary Optic Neuropathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
Expanded Access Use for a single patient of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected with G11778A ND4 Leber Hereditary Optic Neuropathy
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of documented G11778A ND4 LHON-causing mutation
- •Signature of informed consent and assent from the parent/guardian and the patient.
排除标准
- •Contraindications to GS010 product or IVT procedures are to be checked prior to consent signature and treatment injection:
- •Any known allergy or hypersensitivity to GS010 or its constituents.
- •Contraindication to intravitreal injection in any eye.
- •Intravitreal drug delivery to any eye within 30 days prior to the injection
- •Previous vitrectomy in either eye.
- •Narrow angle in any eye contra-indicating pupillary dilation.
- •Presence of disorders or diseases of the eye or adnexa, excluding LHON, which may interfere with visual or ocular assessments, including SD-OCT, during the study period.
- •Presence of known/documented mutations, other than the G11778A ND4 LHON-causing mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system.
- •Presence of systemic or ocular/vision diseases, disorders or pathologies, other than LHON, known to cause or be associated with vision loss, or whose associated treatment(s) or therapy(ies) is/are known to cause or be associated with vision loss.
- •Presence of optic neuropathy from any cause except LHON.
- •Presence of illness or disease that, in the opinion of the Investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system, including Multiple Sclerosis (diagnosis of Multiple Sclerosis must be based on the 2010 Revisions to the McDonald Criteria [Polman 2011]).
- •History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation.
- •Previous treatment with ocular gene therapy in either eye.
- •Subjects who have undergone ocular surgery of clinical relevance (per Investigator assessment) within 90 days prior to injection.
- •Subjects who are unable to tolerate (e.g. the immune modulating regimen) or unable or unwilling to comply with all the protocol requirements.
研究者
相似试验
已完成
2 期
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]Retinitis PigmentosaRetinal DiseasesEye DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal DegenerationRetinitisNCT04945772Nanoscope Therapeutics Inc.27
已完成
1 期
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis PigmentosaRetinitis PigmentosaRetinal DiseasesRetinal DegenerationNCT04919473Nanoscope Therapeutics Inc.11
No Longer Available
不适用
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's DiseaseAlzheimer DiseaseNCT04855955Celltex Therapeutics Corporation
已完成
2 期
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt DiseaseStargardt DiseaseNCT05417126Nanoscope Therapeutics Inc.6
进行中（未招募）
1 期
Dose Escalation Study of Intravitreal 4D-110 in Patients With ChoroideremiaChoroideremiaNCT044834404D Molecular Therapeutics13